Plethico Of India To Reduce CRAMS Work, Citing Lower Margins
This article was originally published in PharmAsia News
Executive Summary
India's Plethico Pharmaceuticals, citing the nation's rising inflation and fuel costs, plans to reduce its contract research and manufacturing services. The firm's CFO said the higher costs and inflation are creating insufficient profit margins as it faces renegotiation of contracts. Plethico also faced added competition in the CRAMS business when Wockhardt entered that aspect of the industry last year. (Click here for more